PURPOSE: The inhibition of c-Src results in a striking reduction in cancer cell invasion, but the effect on cell survival is modest. Defining mechanisms that limit apoptosis following c-Src inhibition could result in an ideal therapeutic approach that both inhibits invasion and leads to apoptosis. In this regard, we discovered a novel feedback loop that results in STAT3 reactivation following sustained c-Src inhibition. Here we define the mechanism underlying this feedback loop and examine the effect of inhibiting it in vivo. EXPERIMENTAL DESIGN: We measured levels and activity of pathway components using PCR, Western blotting, and kinase assays following their manipulation using both molecular and pharmacologic approaches. We used a heterotransplant animal model in which human oral squamous cancer is maintained exclusively in vivo. RESULTS: Following c-Src inhibition, STAT5 is durably inhibited. The inhibition of STAT5A, but not STAT5B, subsequently reduces the expression of suppressors of cytokine signaling 2 (SOCS2). SOCS2 inhibits Janus kinase 2 (Jak2) activity and Jak2-STAT3 binding. SOCS2 expression is necessary for STAT3 inhibition by c-Src inhibitors. Overexpression of SOCS2 is adequate to prevent STAT3 reactivation and to enhance the cytotoxic effects of c-Src inhibition. Likewise, the combination of Jak and c-Src inhibitors led to significantly more apoptosis than either agent alone in vivo. CONCLUSIONS: To our knowledge, ours is the first study that fully defines the mechanism underlying this feedback loop, in which sustained c-Src inhibition leads to diminished SOCS2 expression via sustained inhibition of STAT5A, allowing activation of Jak2 and STAT3, Jak2-STAT3 binding, and survival signals.
PURPOSE: The inhibition of c-Src results in a striking reduction in cancer cell invasion, but the effect on cell survival is modest. Defining mechanisms that limit apoptosis following c-Src inhibition could result in an ideal therapeutic approach that both inhibits invasion and leads to apoptosis. In this regard, we discovered a novel feedback loop that results in STAT3 reactivation following sustained c-Src inhibition. Here we define the mechanism underlying this feedback loop and examine the effect of inhibiting it in vivo. EXPERIMENTAL DESIGN: We measured levels and activity of pathway components using PCR, Western blotting, and kinase assays following their manipulation using both molecular and pharmacologic approaches. We used a heterotransplant animal model in which human oral squamous cancer is maintained exclusively in vivo. RESULTS: Following c-Src inhibition, STAT5 is durably inhibited. The inhibition of STAT5A, but not STAT5B, subsequently reduces the expression of suppressors of cytokine signaling 2 (SOCS2). SOCS2 inhibits Janus kinase 2 (Jak2) activity and Jak2-STAT3 binding. SOCS2 expression is necessary for STAT3 inhibition by c-Src inhibitors. Overexpression of SOCS2 is adequate to prevent STAT3 reactivation and to enhance the cytotoxic effects of c-Src inhibition. Likewise, the combination of Jak and c-Src inhibitors led to significantly more apoptosis than either agent alone in vivo. CONCLUSIONS: To our knowledge, ours is the first study that fully defines the mechanism underlying this feedback loop, in which sustained c-Src inhibition leads to diminished SOCS2 expression via sustained inhibition of STAT5A, allowing activation of Jak2 and STAT3, Jak2-STAT3 binding, and survival signals.
Authors: D W Leaman; S Pisharody; T W Flickinger; M A Commane; J Schlessinger; I M Kerr; D E Levy; G R Stark Journal: Mol Cell Biol Date: 1996-01 Impact factor: 4.272
Authors: R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove Journal: Oncogene Date: 2001-05-03 Impact factor: 9.867
Authors: Anne S Tsao; Dandan He; Babita Saigal; Suyu Liu; J Jack Lee; Srinivasa Bakkannagari; Nelson G Ordonez; Waun Ki Hong; Ignacio Wistuba; Faye M Johnson Journal: Mol Cancer Ther Date: 2007-07 Impact factor: 6.261
Authors: Hanneke Stegeman; Paul N Span; Paul F J W Rijken; Simone C Cockx; Deric L Wheeler; Mari Iida; Albert J van der Kogel; Johannes H A M Kaanders; Johan Bussink Journal: Transl Oncol Date: 2013-08-01 Impact factor: 4.243
Authors: Russell J Schilder; William E Brady; Heather A Lankes; James V Fiorica; Mark S Shahin; Xun C Zhou; Robert S Mannel; Harsh B Pathak; Wei Hu; R Katherine Alpaugh; Anil K Sood; Andrew K Godwin Journal: Gynecol Oncol Date: 2012-06-16 Impact factor: 5.482
Authors: Ming Zhang; Ratnakar Singh; Shaohua Peng; Tuhina Mazumdar; Vaishnavi Sambandam; Li Shen; Pan Tong; Lerong Li; Nene N Kalu; Curtis R Pickering; Mitchell Frederick; Jeffrey N Myers; Jing Wang; Faye M Johnson Journal: Cancer Lett Date: 2017-01-23 Impact factor: 8.679
Authors: Tuhina Mazumdar; Lauren A Byers; Patrick Kwok Shing Ng; Gordon B Mills; Shaohua Peng; Lixia Diao; You-Hong Fan; Katherine Stemke-Hale; John V Heymach; Jeffrey N Myers; Bonnie S Glisson; Faye M Johnson Journal: Mol Cancer Ther Date: 2014-09-05 Impact factor: 6.261